Beyond The Numbers: 6 Analysts Discuss Clorox Stock
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Clorox (NYSE:CLX) show a mix of perspectives, with a notable shift towards a more positive outlook as evidenced by an increase in the average 12-month price target to $148.67 from $131.25. Analysts from firms including Goldman Sachs, DA Davidson, UBS, JP Morgan, Barclays, and B of A Securities have updated their ratings and price targets, reflecting various views on the company's performance and market position. Clorox's financial performance shows strong revenue growth and ROE, but challenges in net margin, ROA, and debt management.
March 01, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clorox has received mixed analyst ratings with a positive shift in the average 12-month price target to $148.67, indicating a bullish sentiment. The company's strong revenue growth and exceptional ROE are positive indicators, though challenges in net margin, ROA, and debt management persist.
The increase in the average 12-month price target suggests a more optimistic outlook from analysts, potentially leading to increased investor confidence and a positive short-term impact on CLX's stock price. However, the mixed nature of the ratings and the identified financial challenges could moderate the extent of this impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100